期刊文献+

口服甲苯磺酸索拉非尼患者的观察及护理 被引量:2

暂未订购
导出
出处 《临床合理用药杂志》 2009年第22期105-106,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献3

二级参考文献20

  • 1吴青妹.肿瘤术后化疗病人焦虑情绪和生活质量调查及健康干预的作用[J].护理研究(下半月),2004,18(12):2193-2194. 被引量:23
  • 2袁志平,罗峰,姜愚,彭枫,邹立群,姚文秀.生物化疗联合沙利度胺治疗晚期肾癌的临床观察[J].四川医学,2006,27(3):261-263. 被引量:4
  • 3周爱萍,孙燕.多靶点抗肿瘤新药索拉非尼的研究进展[J].癌症进展,2006,4(6):529-533. 被引量:57
  • 4丁丽,程刚.多靶点抗肿瘤新药索拉非尼的药理作用及临床研究进展[J].药物不良反应杂志,2007,9(3):153-157. 被引量:12
  • 5[2]Eisen T,Bukowski RM,Staehler M,et al.Randomized phase Ⅲ trial of sorafenib in advanced renal cell carcinoma (RCC):Impact of crossover on survival.ASCO,2006
  • 6[3]Bayer Pharmaceuticals Corporation.Nexavar (sorafenib)[prescribing information].West Haven:Conn,2005
  • 7[4]Escudier B,Szczylik C,Eisen T,et al.Randomized phase Ⅲ trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 439006) in patients with advanced renal cell carcinoma(RCC).J Clin Oncol,ASCO Annual Meeting Proceedings,2005,23:16S[Supplement],LBA4510
  • 8[5]Ratain MJ,Eisen T,Stadler WM,et al.Phase Ⅱ placebocontrolled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.J Clin Oncol,2006,24 (16):2505
  • 9[6]Strumberg D,Richly H,Hilger RA,et al.Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006 in patients with advanced refractory solid tumors.J Clin Oncol,2005 10,23 (5):965
  • 10[7]Biedrzycki BA.Renal cell carcinoma:Today's targeted therapies improving tomorrow's outcomes.ONS News.2006,21 (8Suppl):21 Available online at www.meniscus.com/eval/renal-cell-tx

共引文献42

同被引文献7

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部